People with rare disorders have a worse healthcare experience than those affected by chronic diseases, according to the results of…
Articles by Marta Figueiredo, PhD
The Pulmonary Fibrosis Foundation (PFF) is highlighting for smokers, and ex-smokers, the need to be aware of pulmonary fibrosis (PF)…
Suppressing MBD2, a DNA-binding protein, reduced the number of pro-fibrotic macrophages — a type of immune cell involved…
A Phase 3 clinical trial evaluating Bellerophon Therapeutics’ investigational therapy INOpulse — inhaled nitric oxide — in patients with…
The first wave of COVID-19Â in Europe severely disrupted access to care and raised stress and anxiety in people with…
FibroGen’s experimental antifibrotic therapy pamrevlumab may be more effective than Esbriet (pirfenidone) and Ofev (…
Treatment with inhalable bone morphogenic protein 4 (BMP4) — a soluble signaling molecule involved in the regulation of cellular…
Idiopathic pulmonary fibrosis (IPF) patients showing a lesser decline in lung function after antifibrotic treatment, especially with Ofev (nintedanib),…
A cell therapy approach based on transplanting a type of lung cells called type II alveolar cells halted scarring (fibrosis)…
Increasing the levels of a membrane-repair protein called tripartite motif containing 72 (TRIM72) protected against lung cell injury and lessened…